Arca
Skip to content
Tools
Tools

Neuropathic pain

Drug research and approvals for neuropathic pain: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 234 studies of neuropathic pain are recruiting on ClinicalTrials.gov, Health Canada has authorized 20 drug trials for it since 2013, FDA has 1 approved and 3 open orphan designations naming it, and the EU has 10 authorised medicines for it.

  • Recruiting worldwide: 234
  • Trials authorized in Canada: 20
  • FDA orphan approvals: 1
  • EU medicines: 10

Recruiting now

Newest posted first, of 234 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 20; search them all in Canada trials
Mar 4, 2025Ecstasy to alleviate severe chronic neuropathic pain (ease pain) trial: a randomized controlled pilot trialMethylenedioxymethamphetamine / MethylphenidateSt Michaels HospitalOngoing
Nov 29, 2024A phase 2, randomized, double-blind, active-controlled, dose-ranging, parallel-design study of the efficacy and safety of oral VX-993 in subjects with pain…VX-993 / PregabalinVertex PharmaceuticalsOngoing
May 28, 2024Treatment with psilocybin for chronic neuropathic pain and depression (transcend): an open-label clinical trialPsilocybinCentre for Addiction and Mental HealthOngoing
Apr 25, 2024A double-blind, randomized, placebo-controlled, 4-arm parallel-group, multiple-dose study to assess efficacy and safety of medical cannabis aerosol via the…SQE-001 (tetrahydrocannabinol)Syqe Medical LtdClosed
Feb 21, 2024Psilocybin for enhanced analgesia in chronic neuropathic pain: a randomized controlled pilot trial (peace-pain)Psilocybin (PEX010) / DextromethorphanSt Michaels HospitalOngoing
Apr 26, 2023A multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of…GSK3858279GSKOngoing
Oct 13, 2022Psychotherapy for ketamine's enhanced durability in chronic neuropathic pain: a randomized controlled pilot trial (P-003)KetamineSt Michaels HospitalPending
Jun 27, 2022A randomized, double-blind, placebo-controlled, multicenter, efficacy and safety trial of single cycle tetrodotoxin in the treatment of chemotherapy-induced…Tetrodotoxin for injectionWex Pharmaceuticals IncPending
May 21, 2021Cannabinoids and an anti-inflammatory diet for the treatment of neuropathic pain after spinal cord injury: the catnp studyNabiloneEldon LohOngoing
Apr 23, 2019A randomized, double-blind, placebo-controlled, parallel, 24-week, phase 2a study of topical pirenzepine (WST-057) or placebo in type 2 diabetic patients with…Pirenzepine (WST-057)Winsantor, IncPending

FDA orphan designations

Approved first, then open designations, newest first
Nov 16, 2009QutenzaManagement of neuropathic pain associated with postherpetic neuralgiaAveritas Pharma, Inc.Approved
Sep 13, 2011L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-…Treatment of neuropathic pain in patients with sarcoidosis.Araim Pharmaceuticals, Inc.Designated
Jul 7, 2005Contulakin-GIntrathecal treatment of neuropathic pain associated with spinal cord injuryCognetix, Inc.Designated
Apr 26, 2005L-threonyl-L-prolyl-L-prolyl-L-threonineTreatment of neuropathic pain associated with spinal cord injuryNyxis Neurotherapies, Inc.Designated

Medicines authorised in the EU

Newest first

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.